The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Regional hyperthermia (RHT) as an innovative treatment component: RHT combined with gemcitabine (G) and cisplatin (CIS) in G-pretreated advanced pancreatic cancer (APC).
K. Tschoep-Lechner
No relevant relationships to disclose
N. Dieterle
No relevant relationships to disclose
S. Abdel-Rahman
No relevant relationships to disclose
L. Lindner
No relevant relationships to disclose
C. Salat
No relevant relationships to disclose
S. Ehrke
No relevant relationships to disclose
B. Weber
No relevant relationships to disclose
C. J. Bruns
No relevant relationships to disclose
V. Heinemann
No relevant relationships to disclose
U. Mansmann
No relevant relationships to disclose
R. D. Issels
No relevant relationships to disclose